يعرض 1 - 20 نتائج من 20,161 نتيجة بحث عن '(( significant ((17 decrease) OR (a decrease)) ) OR ( significantly improve decrease ))', وقت الاستعلام: 0.67s تنقيح النتائج
  1. 1
  2. 2
  3. 3
  4. 4
  5. 5
  6. 6
  7. 7
  8. 8
  9. 9

    Voxel-based whole-hemisphere analysis shows regional and dose-dependent decrease of microglia. حسب Francesca Catto (21253435)

    منشور في 2025
    "…<p>(A) Each 3-dimensional map of statistically affected voxels (p < 0.05, with the red scale, representing the significance in decrease of microglia, and the cyan scale, representing the increase in microglia; reference atlas is grey) summarizes all the treated and control samples within a cohort (3 samples per group). …"
  10. 10

    Fig 17 - حسب Zhezhe Zhang (19704587)

    منشور في 2024
    الموضوعات:
  11. 11
  12. 12
  13. 13

    Significant associations in GWAS. حسب Dai Nogimura (21445649)

    منشور في 2025
    الموضوعات:
  14. 14
  15. 15

    Data Sheet 2_Ruxolitinib synergizes with regulatory T cells to improve inflammation but has no added benefits in decreasing albuminuria in SLE.pdf حسب Mi-Ae Lyu (20413646)

    منشور في 2025
    "…UCB-Treg and ruxolitinib combination also downregulates the soluble form of inflammatory cytokines including IFN-γ, IP-10, TNF-α, IL-6, sCD40L, IL-17A, IL-17F, IL-1α, and LIF in cocultures. The addition of ruxolitinib increases UCB-Treg cell persistence in peripheral blood in vivo and decreases the soluble form of human inflammatory cytokines including IFN-γ, TNF-α, and sCD40L in plasma along with improvement of skin lesions in SLE xenografts. …"
  16. 16

    Data Sheet 3_Ruxolitinib synergizes with regulatory T cells to improve inflammation but has no added benefits in decreasing albuminuria in SLE.pdf حسب Mi-Ae Lyu (20413646)

    منشور في 2025
    "…UCB-Treg and ruxolitinib combination also downregulates the soluble form of inflammatory cytokines including IFN-γ, IP-10, TNF-α, IL-6, sCD40L, IL-17A, IL-17F, IL-1α, and LIF in cocultures. The addition of ruxolitinib increases UCB-Treg cell persistence in peripheral blood in vivo and decreases the soluble form of human inflammatory cytokines including IFN-γ, TNF-α, and sCD40L in plasma along with improvement of skin lesions in SLE xenografts. …"
  17. 17

    Data Sheet 1_Ruxolitinib synergizes with regulatory T cells to improve inflammation but has no added benefits in decreasing albuminuria in SLE.pdf حسب Mi-Ae Lyu (20413646)

    منشور في 2025
    "…UCB-Treg and ruxolitinib combination also downregulates the soluble form of inflammatory cytokines including IFN-γ, IP-10, TNF-α, IL-6, sCD40L, IL-17A, IL-17F, IL-1α, and LIF in cocultures. The addition of ruxolitinib increases UCB-Treg cell persistence in peripheral blood in vivo and decreases the soluble form of human inflammatory cytokines including IFN-γ, TNF-α, and sCD40L in plasma along with improvement of skin lesions in SLE xenografts. …"
  18. 18
  19. 19
  20. 20

    Voxel-based whole-brain analysis shows regional and dose-dependent effects of netoglitazone in decreasing plaque count. حسب Francesca Catto (21253435)

    منشور في 2025
    "…Each map represents a 3-dimensional view of statistically affected voxels (p < 0.05), where the red scale indicates a decrease in plaque count, and the cyan scale represents an increase. …"